decisionhealth Newsletters, Coder Pink Sheets - 2009 Issue 12 (December)
Ophthalmology RoundUp: CMS withdraws Avastin Q-code
Subscribe or sign in to view the full article.
Article Overview
This article explains a short-lived CMS coding change affecting ophthalmology practices that report bevacizumab use for retinal disease care. It places the change in the context of the 2009 physician fee schedule, CMS communications, and response from policymakers and specialty groups. The article is useful for billers, coders, and practice managers who track HCPCS updates, Medicare reporting changes, and office-based drug billing transitions.
Why This Topic Matters
Temporary coding changes can affect how practices report drug administration services, especially when CMS replaces or withdraws a code on a short timeline. Understanding the timing and the surrounding policy update helps ophthalmology practices stay aligned with Medicare billing requirements.
What You Will Learn
- How CMS handled a temporary HCPCS coding change for an ophthalmology-related drug service
- What policy and billing timeline changes were described in connection with the code withdrawal
- Which organizations and lawmakers were involved in the public response
- How the article frames the impact on office-based drug reporting for ophthalmology practices
Who Should Read This
- Ophthalmology coders
- Medical billers
- Revenue cycle staff
- Physician practice administrators
- Medicare billing specialists
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com